Spontaneous C-cleavage of a truncated intein as fusion tag to produce tag-free VP1 inclusion body nanoparticle vaccine against CVB3-induced viral myocarditis by the oral route.

Xingmei Qi
Xingmei Qi
Donghua University
Shanghai | China
Qian Lu
Qian Lu
University of Houston
Houston | United States
Jingping Hu
Jingping Hu
University of Oxford
United Kingdom
Sidong Xiong
Sidong Xiong
Jiangsu Key Laboratory of Infection and Immunity

Microb Cell Fact 2019 Apr 4;18(1):66. Epub 2019 Apr 4.

The Jiangsu Key Laboratory of Infection and Immunity, Institutes of Biology and Medical Sciences, Soochow University, Suzhou, 215123, Jiangsu, China.

Background: Oral vaccine is highly desired for infectious disease which is caused by pathogens infection through the mucosal surface. The design of suitable vaccine delivery system is ongoing for the antigen protection from the harsh gastric environment and target to the Peyer's patches to induce sufficient mucosal immune responses. Among various potential delivery systems, bacterial inclusion bodies have been widely used as delivery systems in the field of nanobiomedicine. However, a large number of heterologous complex proteins could be difficult to propagate in E. coli and fusion partners are often used to enhance target protein expression. As a safety concern the fusion protein need to be removed from the target protein to get tag-free protein, especially for the production of protein antigen in vaccinology. Until now, there is no report on how to remove fusion tag from inclusion body particles in vitro and in vivo. Coxsackievirus B3 (CVB3) is a leading causative agent of viral myocarditis and orally protein vaccine is high desired for CVB3-induced myocarditis. In this context, we explored a tag-free VP1 inclusion body nanoparticles production protocol though a truncated Ssp DnaX mini-intein spontaneous C-cleavage in vivo and also exploited the VP1 inclusion bodies as an oral protein nanoparticle vaccine to protect mice against CVB3-induced myocarditis.

Results: We successfully produced the tag-free VP1 inclusion body nanoparticle antigen of CVB3 and orally administrated to mice. The results showed that the tag-free VP1 inclusion body nanoparticles as an effective antigen delivery system targeting to the Peyer's patches had the capacity to induce mucosal immunity as well as to efficiently protect mice from CVB3 induce myocarditis without any adjuvant. Then, we proposed the use of VP1 inclusion body nanoparticles as good candidate for oral vaccine to against CVB3-induced myocarditis.

Conclusions: Our tag-free inclusion body nanoparticles production procedure is easy and low cost and may have universal applicability to produce a variety of tag-free inclusion body nanoparticles for oral vaccine.

Download full-text PDF

http://dx.doi.org/10.1186/s12934-019-1115-zDOI Listing
April 2019
6 Reads

Publication Analysis

Top Keywords

inclusion body
vp1 inclusion
body nanoparticles
tag-free vp1
oral vaccine
vaccine cvb3-induced
protect mice
nanoparticle vaccine
tag-free inclusion
delivery system
inclusion bodies
delivery systems
spontaneous c-cleavage
peyer's patches
target protein
fusion tag
nanoparticles production
viral myocarditis


(Supplied by CrossRef)
Article in J Drug Deliv
A Salvador et al.
J Drug Deliv 2011
Article in Vaccine
JC Aguilar et al.
Vaccine 2007
Article in Pharm Pat Anal
AS Cordeiro et al.
Pharm Pat Anal 2016
Article in Trends Pharmacol Sci
SR Bonam et al.
Trends Pharmacol Sci 2017
Article in Nanomedicine (Lond)
M Skwarczynski et al.
Nanomedicine (Lond) 2014
Article in Nanomedicine (Lond)
TM Fahmy et al.
Nanomedicine (Lond) 2008
Article in Chem Rev
DJ Irvine et al.
Chem Rev 2015
Article in Vaccines (Basel)
A Vartak et al.
Vaccines (Basel) 2016
Article in Allergy
H Pohlit et al.
Allergy 2017
Article in Eur J Immunol
P Maurer et al.
Eur J Immunol 2005
Article in Nat Nanotechnol
MA Dobrovolskaia et al.
Nat Nanotechnol 2007

Similar Publications